Prothena CORP Public LTD CO DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Prothena Corporation plc announces its 2026 Annual General Meeting to address director elections, auditor ratification, and executive compensation.
NASDAQ
Prothena Corporation plc announced third quarter 2025 financial results and significant advancements in its late-stage clinical programs for neurodegenerative and rare diseases.
NASDAQ
Prothena Corporation Public Limited Company has filed definitive additional proxy materials with the SEC.
NASDAQ
Prothena Corporation plc is convening an Extraordinary General Meeting to approve a capital reduction, aiming to create distributable reserves for potential future shareholder distributions, including a share redemption program.
NASDAQ
Prothena Corporation has filed a definitive proxy statement with the SEC, related to its upcoming shareholder meeting.
NASDAQ
Prothena Corporation is holding its Annual General Meeting on May 13, 2025, seeking shareholder approval for director elections, auditor ratification, executive compensation, and an amendment to the 2018 Long Term Incentive Plan.
NASDAQ
Prothena Corporation has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
Prothena Corporation is holding its Annual General Meeting on May 14, 2024, to vote on director elections, auditor ratification, executive compensation, and an amendment to the long-term incentive plan.